Install
Zacks Small Cap Research coverage specifically looks to focus on small and micro-cap companies that are under followed or under valued by Wall Street.
- 38articles · 30d
- 3+ day agolatest article
- Aug 17, 2026earliest in window
- 0%with images
- 298avg words
- Economy, Business & Finance 33
- Finance & Business 25
- News 21
- Health & Wellness 10
- Medical 8
- Business & Industrial 6
- Industrial 5
- Health 4
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
GOTRF: Surebet Discovery Site Visit confirms our positive outlook for the project. Drilling continues to hit mineralization, expand the footprint, and remains open.
3+ day, 15+ hour ago (522+ words) //s27.q4cdn.com/906368049/files/pictures/2026/09102026_GOTRF_1.png GOTRF: Surebet Discovery Site Visit confirms our positive outlook for the project. Drilling continues to hit mineralization, expand the footprint, and remains open. In August 2026, the analyst travelled to northern British Columbia to conduct a due…...
CPKF Posts Another Strong Quarter with Diluted EPS Up 75% Year over Year
4+ day, 19+ hour ago (278+ words) By Ann Heffron, CFA, CPA READ THE FULL CPKF RESEARCH REPORT Chesapeake Financial (OTCQX: CPKF) produced another strong quarter with 2026 second quarter net earnings surging $2.3 million, or 74%, to $5.5 million year over year, while 2026’s second quarter diluted EPS rose $0.50, or…...
UHAL: U-Haul Reported 1Q FY2027 Financial Results
5+ day, 19+ hour ago (334+ words) By Steven Ralston, CFA READ THE FULL UHAL RESEARCH REPORT On August 20, 2026, U-Haul held its 20th Annual Virtual Analyst and Investor Meeting, which was largely composed of answering analyst and investor questions. Highlights from the 20th Annual Virtual Analyst & Investor Meeting Toy…...
BENF: Beneficient Releases 1st Fiscal Quarter Results (Period Ending 6/30/26)
1+ week, 3+ day ago (376+ words) By Tom Kerr, CFA READ THE FULL BENF RESEARCH REPORT 1st Quarter 2027 Results (period ending June 30, 2026) On August 14, 2026, Beneficient (NASDAQ: BENF) announced fiscal 1st quarter results for the period ending 6/30/26. Beneficient reported $212.5 million of investments at fair value as of June 30, 2026, up…...
TNXP: $11.0 Million in Tonmya® Net Revenue in 2Q26
1+ week, 4+ day ago (233+ words) READ THE FULL TNXP RESEARCH REPORT $11.0 Million in Net Revenue for Tonmya® in 2Q26 Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is continuing the commercial launch of Tonmya® following its approval in August 2025 and commercial launch in November 2025. Sales metrics for the…...
CVKD: Advancing Partnering Process for Cardiac Acute Critical Care Franchise
1+ week, 6+ day ago (166+ words) READ THE FULL CVKD RESEARCH REPORT Launches Strategic Partnering Process for Cardiac Acute Critical Care Franchise Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) has launched a structured strategic partnering process for its Cardiac Acute Critical Care Franchise that is centered on three…...
CEO Chat with Tim Harrison, Managing Director of Ionic Rare Earths Limited
1+ week, 6+ day ago (679+ words) OTCQB: IXRRF ASX: IXR Tim Harrison: Hi Tom, good to be here. TK: I'm going to start with a series of questions. Before we get into your operations and your future development plans, some people may not be familiar with…...
HURA: Milestone Progression Over Next 12 Months
2+ week, 4+ day ago (71+ words) READ THE FULL HURA RESEARCH REPORT TuHURA generated no revenues in 2Q:26 and expended $8.8 million on operational activities related to advancing IFx-2.0, TBS-2025, and other programs, producing a net loss of $9.2 million or $0.14 per share. For the quarter ending June 30th, 2026, and…...
CING: Second Quarter Results
3+ week, 4+ day ago (305+ words) READ THE FULL CING RESEARCH REPORT Cingulate, Inc. (NASDAQ: CING) reported second quarter 2026 results on August 13th, 2026. During the three-month period, the company generated no revenue and recorded operating expense of $5.4 million. Since the end of the first quarter, cash balances…...
AEMD: Oncology Study Advances; Cost-Efficient Preclinical Activities Regarding Other Diseases Continue
3+ week, 4+ day ago (212+ words) READ THE FULL AEMD RESEARCH REPORT Early observations from 1st two cohorts showed consistent improvements in immune function Aethlon Medical (NASDAQ: AEMD), a clinical-stage medical therapeutic company advancing its lead asset, the Hemopurifier, to treat cancer and life-threatening viral infections, reported…...